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Glioblastoma (GBM) is the second most common, but
most aggressive, primary brain tumor. Despite aggressive
multimodal therapy consisting of surgery, radiation, and
chemotherapy, the outcome of patients with GBM
remains poor with 5-year survival rates of <10%. There-
fore, new, targeted treatments are needed to improve out-
comes, and adoptive T cell immunotherapy has the
potential to fulfill this need. T cells genetically modified
with chimeric antigen receptors (CARs) specific for cell
surface antigens expressed in GBM such as HER2, EphA2,
EGFRvIII, and IL13R (a1 and a2) have shown promising
anti-GBM activity in preclinical GBM models. However,
the majority of studies have been conducted in xenograft
models that do not recapitulate the immunosuppressive
tumor microenvironment. The goal of this project is now
to adapt the established GL261 immune competent
murine GBM model for the preclinical optimization of
GBM-targeted CAR T cell therapies.
Since GL261 were readily killed by IL13R-specific
human CAR T cells, we generated a retroviral vector
encoding an IL13R-specific murine CAR with a CD28.
CD3z endodomain. CD3-activated splenocytes were trans-
duced with VSV-G pseudotyped retroviral particles,
sorted, and used for functional in vitro studies. In contrast
to non-transduced T cells, IL13R-specific murine CAR T
cells recognize GL261, as judged by their ability to prolif-
erate, secrete cytokines and kill GL261 cells in co-culture
assays. IL13R-negative cells did not activate IL13R-specific
murine CAR T cells, confirming antigen specificity.
Animal experiments are in progress to evaluate the safety
and efficacy of IL13R-specific murine CAR T cells in vivo.
In summary, our results indicate that is feasible to
develop an immune competent murine GBM-targeted
T cell immunotherapy model. Such a model will not
only facilitate the translation of these therapies into the
clinic, but will also allow us to realistically study how to
best combine T cell therapy with other GBM-targeted
therapies.
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